I’m excited to announce this TechCrunch Live event. Cambrian BioPharma startup develops life-changing technology while pioneering a radical approach to a pharmaceutical company. Don’t miss this TechCrunch Live takes place May 3 at 12 PM PDT. Register here. Viewing and sharing is free.
Cambrian BioPharma sees itself as a new pharmaceutical company with a revolutionary approach to developing and managing drug development. James Peyer, Ph. D., co-founded the company in 2019, and it has since raised more than $180 million to accelerate the development of drugs designed to target the causes of age-related disease.
But this is not the most interesting part. Peer’s executive team was able to attract top talent by giving them a greater amount of equity than traditional drug companies. Instead of developing pharmaceuticals in-house of Cambrian BioPharma, the company essentially spins the solution with senior scientists sitting in the C-suite along with veteran Cambrian BioPharma executives who will help run the new company.
Marianna Sayenko of Future Ventures also speaks at this TechCrunch Live event. She sits on Cambrian BioPharma’s Board of Directors and has invested in the company’s Series A, B, and C rounds. Together, the two will disassemble Cambrian BioPharma’s unique business model and explain why this operation works.
Marianna is also a co-founder and partner at Future Ventures, where she sits on the boards of several deep tech medical startups, including Deep Genomics, Earthshot Labs, and Gameto. She brings with her a wealth of knowledge and experience from her time at Future Ventures, formerly Khosla Ventures, Threshold Ventures, and DFJ. It’s a pleasure for her and James Beer to talk about the innovative work of Cambrian BioPharma.
Register here for the TechCrunch Live event.